摘要
目的探讨空腹血糖受损(IFG)患者脂联素水平的变化。方法入选糖耐量正常(NGT)、孤立性空腹血糖受损(I-IFG)、孤立性糖耐量低减(I-IGT)、空腹血糖受损并糖耐量低减(IFG/IGT)、新发2型糖尿病(T2DM)各30例,采用酶联免疫吸附法(ELISA)测定血清脂联素,同时检测胰岛素水平及血糖、血脂,计算胰岛素抵抗指数(HOMA-IR)。结果I-IFG组、I-IGT组、IFG/IGT组及新发T2DM组脂联素均明显低于NGT组(P均<0.01);新发T2DM组和IFG/IGT组的HOMA-IR均>I-IGT组>I-IFG组>NGT组,各组间差异有统计学意义(P均<0.05或P<0.01);脂联素与空腹血糖(FBG)、餐后2 h血糖(2HBG)及HOMA-IR呈负相关(P均<0.01)。结论在I-IFG阶段已存在脂联素水平降低,胰岛素抵抗增加,具有向糖尿病转化及并发大血管病变的风险,提高脂联素水平可为糖尿病及其并发症的防治提供一条新的思路。
Objective To investigate the changes of serum adiponectin concentrations in impaired fasting glycaemia subjects. Method 30 subjects with normal glucose tolerance （NGT）, 30 cases of isolated impaired fasting glycaemia （I-IFG）, 30 cases of isolated impaired glucose tolerance（I-IGT）, 30 cases of combined I-IFG and I-IGT（IFG/IGT）, and 30 patients with newly diagnosed type 2 diabetes（T2DM）were examined in this study. Serum adiponectin was determined by enzyme-linked immunosorbent assay （ELISA）. Levels of insulin, glucose and lipid in blood were measured, and insulin resistance index （HOMA-IR） was calculated. Result Concentrations of adiponectin in I-IFG,I-IGT,IFG/IGT and newly diagnosed T2DM groups were significantly lower than the NGT group （P〈0.01）. The value of HOMA-IR was in the order of newly diagnosed T2DM and IFG/IGT groups 〉I-IGT group〉I-IFG group〉NGT group, and the difference was significant （P〈0.05 or P〈0.01）. The level of adiponectin was negatively correlated with the level of fasting blood glucose（FBG）, 2 h postprandial glucose（2hBG） and HOMA-IR （P〈0.01）. Conclusion I-IFG subjects with low concentration of serum adiponectin and an increased insulin resistance index are at risk of developing diabetes mellitus and macrovascular complication. Increasing the concentration of adiponectin may be used to treat and prevent the development of diabetes mellitus and its complication.
出处
《热带医学杂志》
CAS
2008年第6期578-580,共3页
Journal of Tropical Medicine
基金
广东省卫生厅科技项目(No.WSTJJ20061028440102196506253249)
关键词
空腹血糖受损
脂联素
糖耐量低减
2型糖尿病
胰岛素抵抗
impaired fasting glycaemia
adiponectin
impaired glucose tolerance
type 2 diabetes mellitus
insulin resistance
